List of Trudhesa drug patents

Trudhesa is owned by Impel Neuropharma.

Trudhesa contains Dihydroergotamine Mesylate.

Trudhesa has a total of 6 drug patents out of which 0 drug patents have expired.

Trudhesa was authorised for market use on 02 September, 2021.

Trudhesa is available in spray, metered;nasal dosage forms.

Trudhesa can be used as nasal administration of dihydroergotamine mesylate by metered spray for the acute treatment of migraine with or without aura.

The generics of Trudhesa are possible to be released after 04 January, 2039.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9550036 IMPEL NEUROPHARMA Nasal drug delivery device
Sep, 2032

(9 years from now)

US10507295 IMPEL NEUROPHARMA Nasal drug delivery device
Dec, 2032

(9 years from now)

US10940278 IMPEL NEUROPHARMA Nozzles for nasal drug delivery
Jan, 2033

(9 years from now)

US9919117 IMPEL NEUROPHARMA Nozzles for nasal drug delivery
Mar, 2033

(10 years from now)

US11266799 IMPEL NEUROPHARMA In-line nasal delivery device
Nov, 2036

(13 years from now)

US11185497 IMPEL NEUROPHARMA Intranasal delivery of dihydroergotamine by precision olfactory device
Jan, 2039

(15 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Sep 2, 2024

Drugs and Companies using DIHYDROERGOTAMINE MESYLATE ingredient

Market Authorisation Date: 02 September, 2021

Treatment: Nasal administration of dihydroergotamine mesylate by metered spray for the acute treatment of migraine with or without aura

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in